ArticleBrain and behavior2025
Inductive and Transfer Learning-Based Hybrid Model Techniques for Accurate and Automated Diagnosis of Neurological Diseases.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inductive and Transfer Learning-Based Hybrid Model Techniques for Accurate and Automated Diagnosis of Neurological Diseases.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeThis study presents NeuroDL, a novel deep learning-based diagnostic framework designed for the automated detection of brain tumors and Alzheimer's disease (AD) using magnetic resonance imaging (MRI). The objective is to enhance diagnostic precision and efficiency in neurology through advanced computer-aided decision support.
methodsNeuroDL utilizes convolutional neural networks (CNNs) trained on two publicly available, annotated MRI datasets. The proposed pipeline integrates optimized preprocessing, including normalization, skull stripping, and data augmentation, followed by CNN-based feature extraction and classification. Transfer learning and fine-tuning were employed to improve generalization on limited medical data.
resultsExperimental evaluations show that NeuroDL achieves 96.8% classification accuracy for brain tumor detection and 92.4% accuracy for Alzheimer's disease diagnosis. The method also achieves an average F1-score of 0.965, precision of 0.969, and recall of 0.962 for brain tumors, and an F1-score of 0.918, precision of 0.921, and recall of 0.916 for AD. These results outperform state-of-the-art benchmarks on the same datasets.
conclusionPotential for real-time clinical deployment. It addresses key limitations of existing CAD systems by providing a unified, dual-disease diagnosis model with statistically validated performance gains. NeuroDL paves the way for reliable, scalable, and automated neurological disease diagnosis using deep learning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.